• 1
    NHLBI/WHO-Workshop report. Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung, and Blood Institute. Publication no. 95–3659, Jan 1995.
  • 2
    Zimmermann B, Chambers C, Forsyth L. Allergy in asthma. II. The highly atopic infant and chronic asthma. J Allergy Clin Immunol 1998;81:7176.
  • 3
    Delacourt C, Lable D, Vassoult A, Brunet Langot D, De Blic J, Scheinmann P. Sensitization to inhalant allergens in wheezing infants is predictive of the development of infantile asthma. Allergy 1994;49:843847.
  • 4
    Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434457.
  • 5
    Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:971977.
  • 6
    Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709722.
  • 7
    Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;2:912915.
  • 8
    Bousquet J, Michel FB. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf 1994;10:517.
  • 9
    Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990;85:473479.
  • 10
    Bousquet J, Lockey RF, Malling H-J editors. WHO Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998;53 Suppl 44:142.
  • 11
    Malling H-J, Abreu-Nogueira J, Alvarez-Cuesta E, et al. Local Immunotherapy. Position Paper by the Working Group on Local Immunotherapy of the EAACI Subcommittee and the ESPACI Immunotherapy Subcommittee. Allergy 1998;53:933944.
  • 12
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol (Madr) 1990;18:277284.
  • 13
    Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen induced rhinitis: a double blind study. J Investig Allergol Clin Immunol 1995;5:2530.
  • 14
    Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309313.
  • 15
    Clavel R, Bousquet J, André C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53:493498.
  • 16
    Feliziani V, Lattuada G, Parmiani S, Dall'aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extract. A double-blind study. Allergol Immunopathol Immunol 1995;23:224230.
  • 17
    Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26:12531261.
  • 18
    Passalacqua G, Albano M, Fragonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629632.DOI: 10.1016/s0140-6736(97)07055-4
  • 19
    Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662672.
  • 20
    Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54:249260.
  • 21
    Guidelines for the diagnosis and management of asthma. Expert Panel Report. J Allergy Clin Immunol 1991;88:425534.
  • 22
    Malling H-J, Weeke B editors. EAACI Position Paper. Immunotherapy Allergy 1993;48 Suppl 14:730.
  • 23
    Carreira J, Rubio M, Herrero T, et al. Collaborative clinical assay of the biological potency of allergen skin test extracts. Clin Allergy 1984;14:503507.
  • 24
    Carreira J, Lombardero M, Ventas P. New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. Arbeiten aus dem Paul-Ehrlich-Institut. Stuttgart: Gustav Fischer Verlag, 1994.
  • 25
    Dreborg S, Frew A. Position paper. Allergen standardization and skin tests. Allergy 1993;48 Suppl 14:4982.
  • 26
    Ventas P, Lombardero M, Duffort O, Carreira J. Cuantificacion de los alergenos Der p 1 y Der f 1 de los acaros del polvo domestico y Fel d 1 de gato mediante una ELISA en fase solida. Rev Esp Alergol Inmunol Clin 1990;5:7175.
  • 27
    Block JH. The oral administration of pollen. J Lab Clin Med 1927;12:1156.
  • 28
    Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children. Pediatr Allergy Immunol 1997;8:2127.
  • 29
    Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92:229236.
  • 30
    Horak F, Stubner P, Berger UE, et al. Immunotherapy with sublingual birch pollen extract. A short term double-blind placebo study. J Investig Allergol Clin Immunol 1998;8:165171.
  • 31
    Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis and asthma due to house dust mite. Clin Allergy 1986;16:483491.
  • 32
    Malling H-J, Djurup R. Diagnosis and immunotherapy of mould allergy. VII. IgG subclass response and relation to clinical efficacy of immunotherapy with Cladosporium. Allergy 1987;43:6070.
  • 33
    Malling H-J. Sublingual immunotherapy [Editorial]. Clin Exp Allergy 1996;26:12281231.
  • 34
    Almagro E, Asensio O, Bartolomé JM, et al. Estudio multicéntrico de farmacovigilancia de inmunoterapia sublingual en pacientes alérgicos. Allergol Immunopathol (Madr) 1995;23:153159.
  • 35
    Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997;100:122112.